ClinicaliQ Trial Snapshot
- A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF — Recruiting • Phase III • Cardiology / Cardiovascular • NCT07761117.
- What is being tested: Elecoglipron, a novel therapeutic agent, is being evaluated against placebo for its effects on cardiovascular outcomes in patients with HFpEF or HFmrEF through a Phase III randomized controlled trial.
- Patient eligibility overview: The trial enrolls adult participants diagnosed with heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF), regardless of whether they have type 2 diabetes mellitus.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.
Eligibility Snapshot
- : * Left ventricular ejection fraction (LVEF) of > 40% within 12 months prior to screening. * Structural heart disease evidence. * HF diagnosed with New York Heart Association (NYHA) Class II-IV at the time of screening.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.